, Tracking Stock Market Picks
Enter Symbol:
Opexa Therapeutics, Inc. (OPXA) [hlAlert]

down 76.10 %

Opexa Therapeutics, Inc. (OPXA) rated Buy with price target $4 by Aegis Capital

Posted on: Friday,  May 30, 2014  12:00 AM ET by Aegis Capital

Aegis Capital rated Buy Opexa Therapeutics, Inc. (NASDAQ: OPXA) on 05/30/2014, when the stock price was $1.59. Since
then, Opexa Therapeutics, Inc. has lost 76.10% as of 01/26/2016's recent price of $0.38.
If you would have followed this Aegis Capital's recommendation on OPXA, you would have lost 76.1% of your investment in 606 days.

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/30/2014 12:00 AM Buy
1.59 4.00
as of 10/17/2014
1 Week up  10.12 %
1 Month down  -19.44 %
3 Months down  -42.00 %
1 YTD down  -45.28 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy